Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2 Thoracic 1 Other solid neoplasm 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Colorectal Neoplasms 1

Interventions

Oxaliplatin 1439 Fluorouracil 1319 Capecitabine 1114 Gemcitabine 1057 Leucovorin 939 Bevacizumab 847 Irinotecan 830 Cisplatin 676 Radiotherapy 560 Cetuximab 482 pembrolizumab 435 Paclitaxel 401 Drug Therapy 358 Nivolumab 350 130-nm albumin-bound paclitaxel 329 Docetaxel 290 Sorafenib 288 S 1 (combination) 279 Folfox protocol 266 Albumin-Bound Paclitaxel 263 Surgical Procedures, Operative 258 lenvatinib 222 sintilimab 218 tislelizumab 214 durvalumab 212 regorafenib 209 Magnetic Resonance Spectroscopy 205 apatinib 204 Radiosurgery 204 Neoadjuvant Therapy 190

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Maximum Tolerated Dose × Gastrointestinal × Clear all

NCT05212012 2025-10-03

MEFOX

AIO-Studien-gGmbH

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡